Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

URGN – UroGen Pharma Ltd.

URGN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

14.03

Margin Of Safety %

Put/Call OI Ratio

0.5

EPS Next Q Diff

0.23

EPS Last/This Y

2.49

EPS This/Next Y

2.2

Price

46.97

Target Price

58.25

Analyst Recom

1.25

Performance Q

76.61

Upside

-248.3%

Beta

1.59

Ticker: URGN




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13URGN39.520.450.096717
2026-07-14URGN39.250.450.676729
2026-07-15URGN39.860.470.586754
2026-07-16URGN39.980.440.026773
2026-07-17URGN40.30.420.076997
2026-07-20URGN41.130.480.035888
2026-07-21URGN43.920.480.045877
2026-07-22URGN42.120.490.005833
2026-07-23URGN42.550.490.435842
2026-07-24URGN40.930.490.105879
2026-07-27URGN41.380.490.005896
2026-07-28URGN40.850.490.005896
2026-07-29URGN40.430.490.035914
2026-07-30URGN410.490.005918
2026-07-31URGN38.20.481.105923
2026-08-03URGN38.670.500.165945
2026-08-04URGN39.770.490.196047
2026-08-05URGN46.40.490.766056
2026-08-06URGN45.530.500.067004
2026-08-07URGN46.940.500.007016
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13URGN39.5072.0- -0.84
2026-07-14URGN39.1972.0- -0.84
2026-07-15URGN39.8572.0- -0.84
2026-07-16URGN40.0072.0- -0.84
2026-07-17URGN40.2473.1- -0.80
2026-07-20URGN41.0973.1- -0.80
2026-07-21URGN43.9173.3- -0.78
2026-07-22URGN42.1673.3- -0.78
2026-07-23URGN42.5373.3- -0.78
2026-07-24URGN40.9274.8- -0.70
2026-07-27URGN41.4574.8- -0.70
2026-07-28URGN40.8874.8- -0.70
2026-07-29URGN40.4674.8- -0.70
2026-07-30URGN41.1274.8- -0.70
2026-07-31URGN38.2374.8- -0.70
2026-08-03URGN38.6574.8- -0.70
2026-08-04URGN38.6574.8- -0.70
2026-08-05URGN46.3474.8- -0.70
2026-08-06URGN45.6374.8- -0.70
2026-08-07URGN46.9774.8- -0.70
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13URGN-0.491.1215.34
2026-07-14URGN-0.611.1215.34
2026-07-15URGN-0.611.1215.34
2026-07-16URGN-0.611.1215.34
2026-07-17URGN-0.611.1215.34
2026-07-20URGN-0.611.1515.34
2026-07-21URGN-0.611.1515.34
2026-07-22URGN-0.611.1515.34
2026-07-23URGN-0.611.1515.34
2026-07-24URGN-0.611.1515.34
2026-07-27URGN-0.611.1414.03
2026-07-28URGN-0.611.1414.03
2026-07-29URGN-0.611.1414.03
2026-07-30URGN-0.611.1414.03
2026-07-31URGN-0.611.1414.03
2026-08-03URGN-0.610.1714.03
2026-08-04URGN-0.610.1714.03
2026-08-05URGN-0.520.1714.03
2026-08-06URGN-0.520.1714.03
2026-08-07URGN-0.520.1714.03
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

-0.52

Institutional Transactions

0.17

Beta

1.59

Average Sales Estimate Current Quarter

61

Average Sales Estimate Next Quarter

75

Fair Value

Quality Score

29

Growth Score

53

Sentiment Score

99

Actual DrawDown %

2.2

Max Drawdown 5-Year %

-82.6

Target Price

58.25

P/E

Forward P/E

15.5

PEG

P/S

12.16

P/B

P/Free Cash Flow

EPS

-1.99

Average EPS Est. Cur. Y​

-0.7

EPS Next Y. (Est.)

1.49

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-51.73

Relative Volume

1.29

Return on Equity vs Sector %

46.4

Return on Equity vs Industry %

62.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.2

EBIT Estimation

URGN Healthcare
$46.96
📉
Swing / Pullback
Buy the dip on strong trends
47 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
1/15
Valuation
9/20
TP/AR
4/10
Options
7/10
RSI
69.5
Range 1M
91.4%
Sup Dist
4.7%
🚀
Momentum Growth
Ride accelerating trends
71 /100
WATCH
Momentum
24/25
Growth
29/30
Estimates
3/20
Inst/Vol
8/15
Options
7/10
EPS Yr
93%
EPS NY
1457.4%
52W%
96.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +14.8% upside
Quality
7/30
Valuation
4/30
Growth
22/25
Stability
8/10
LT Trend
4/5
Upside
+14.8%
Quality
29
URGN — P/E HistoricalBiotechnology
UroGen Pharma Ltd.
Sector: Healthcare
Industry: Biotechnology
Employees: 300
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN

Latest News

Caricamento notizie per URGN
stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today
news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025
marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance
stock history URGN – UroGen Pharma Ltd. invest stock market
stock prices URGN premarket after hours
ticker URGN fair value insiders trading

URGN – UroGen Pharma Ltd.

URGN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

14.03

Margin Of Safety %

Put/Call OI Ratio

0.5

EPS Next Q Diff

0.23

EPS Last/This Y

2.49

EPS This/Next Y

2.2

Price

46.97

Target Price

58.25

Analyst Recom

1.25

Performance Q

76.61

Upside

-248.3%

Beta

1.59

Ticker: URGN




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13URGN39.520.450.096717
2026-07-14URGN39.250.450.676729
2026-07-15URGN39.860.470.586754
2026-07-16URGN39.980.440.026773
2026-07-17URGN40.30.420.076997
2026-07-20URGN41.130.480.035888
2026-07-21URGN43.920.480.045877
2026-07-22URGN42.120.490.005833
2026-07-23URGN42.550.490.435842
2026-07-24URGN40.930.490.105879
2026-07-27URGN41.380.490.005896
2026-07-28URGN40.850.490.005896
2026-07-29URGN40.430.490.035914
2026-07-30URGN410.490.005918
2026-07-31URGN38.20.481.105923
2026-08-03URGN38.670.500.165945
2026-08-04URGN39.770.490.196047
2026-08-05URGN46.40.490.766056
2026-08-06URGN45.530.500.067004
2026-08-07URGN46.940.500.007016
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13URGN39.5072.0- -0.84
2026-07-14URGN39.1972.0- -0.84
2026-07-15URGN39.8572.0- -0.84
2026-07-16URGN40.0072.0- -0.84
2026-07-17URGN40.2473.1- -0.80
2026-07-20URGN41.0973.1- -0.80
2026-07-21URGN43.9173.3- -0.78
2026-07-22URGN42.1673.3- -0.78
2026-07-23URGN42.5373.3- -0.78
2026-07-24URGN40.9274.8- -0.70
2026-07-27URGN41.4574.8- -0.70
2026-07-28URGN40.8874.8- -0.70
2026-07-29URGN40.4674.8- -0.70
2026-07-30URGN41.1274.8- -0.70
2026-07-31URGN38.2374.8- -0.70
2026-08-03URGN38.6574.8- -0.70
2026-08-04URGN38.6574.8- -0.70
2026-08-05URGN46.3474.8- -0.70
2026-08-06URGN45.6374.8- -0.70
2026-08-07URGN46.9774.8- -0.70
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13URGN-0.491.1215.34
2026-07-14URGN-0.611.1215.34
2026-07-15URGN-0.611.1215.34
2026-07-16URGN-0.611.1215.34
2026-07-17URGN-0.611.1215.34
2026-07-20URGN-0.611.1515.34
2026-07-21URGN-0.611.1515.34
2026-07-22URGN-0.611.1515.34
2026-07-23URGN-0.611.1515.34
2026-07-24URGN-0.611.1515.34
2026-07-27URGN-0.611.1414.03
2026-07-28URGN-0.611.1414.03
2026-07-29URGN-0.611.1414.03
2026-07-30URGN-0.611.1414.03
2026-07-31URGN-0.611.1414.03
2026-08-03URGN-0.610.1714.03
2026-08-04URGN-0.610.1714.03
2026-08-05URGN-0.520.1714.03
2026-08-06URGN-0.520.1714.03
2026-08-07URGN-0.520.1714.03
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

-0.52

Institutional Transactions

0.17

Beta

1.59

Average Sales Estimate Current Quarter

61

Average Sales Estimate Next Quarter

75

Fair Value

Quality Score

29

Growth Score

53

Sentiment Score

99

Actual DrawDown %

2.2

Max Drawdown 5-Year %

-82.6

Target Price

58.25

P/E

Forward P/E

15.5

PEG

P/S

12.16

P/B

P/Free Cash Flow

EPS

-1.99

Average EPS Est. Cur. Y​

-0.7

EPS Next Y. (Est.)

1.49

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-51.73

Relative Volume

1.29

Return on Equity vs Sector %

46.4

Return on Equity vs Industry %

62.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.2

EBIT Estimation

URGN Healthcare
$46.96
📉
Swing / Pullback
Buy the dip on strong trends
47 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
1/15
Valuation
9/20
TP/AR
4/10
Options
7/10
RSI
69.5
Range 1M
91.4%
Sup Dist
4.7%
🚀
Momentum Growth
Ride accelerating trends
71 /100
WATCH
Momentum
24/25
Growth
29/30
Estimates
3/20
Inst/Vol
8/15
Options
7/10
EPS Yr
93%
EPS NY
1457.4%
52W%
96.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +14.8% upside
Quality
7/30
Valuation
4/30
Growth
22/25
Stability
8/10
LT Trend
4/5
Upside
+14.8%
Quality
29
URGN — P/E HistoricalBiotechnology
UroGen Pharma Ltd.
Sector: Healthcare
Industry: Biotechnology
Employees: 300
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN

Latest News

Caricamento notizie per URGN
stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today
news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025
marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance
stock history URGN – UroGen Pharma Ltd. invest stock market
stock prices URGN premarket after hours
ticker URGN fair value insiders trading